Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · S

S. 2130 (97th)

Orphan Drug Act

openUnited States· United States Congress· EN

Introduced

23 February 1982

Last action

26 February 1982 · Committee

Status

Committee on Labor and Human Resources requested executive comment from Health and Human Services Department; GAO; OMB.

Sponsors

Sen. Kassebaum, Nancy Landon [R-KS], Sen. Hatfield, Mark O. [R-OR], Sen. Jackson, Henry M. [D-WA], Sen. Metzenbaum, Howard M. [D-OH], Sen. Nunn, Sam [D-GA], Sen. Pell, Claiborne [D-RI], Sen. Randolph, Jennings [D-WV], Sen. Williams, Harrison A., Jr. [D-NJ], Sen. Cranston, Alan [D-CA], Sen. Riegle, Donald W., Jr. [D-MI], Sen. Moynihan, Daniel Patrick [D-NY], Sen. Zorinsky, Edward [D-NE], Sen. Roth Jr., William V. [R-DE], Sen. Andrews, Mark [R-ND], Sen. Cochran, Thad [R-MS], Sen. Stevens, Ted [R-AK], Sen. Weicker, Lowell P., Jr. [R-CT], Sen. Leahy, Patrick J. [D-VT], Sen. Sarbanes, Paul S. [D-MD], Sen. Cannon, Howard W. [D-NV], Sen. Burdick, Quentin N. [D-ND], Sen. Levin, Carl [D-MI], Sen. Glenn, John H., Jr. [D-OH], Sen. Hayakawa, Samuel Ichiye [R-CA], Sen. DeConcini, Dennis [D-AZ], Sen. Melcher, John [D-MT], Sen. Quayle, Dan [R-IN], Sen. Cohen, William S. [R-ME], Sen. Ford, Wendell H. [D-KY]

Subjects

Healthcare

Source updated

29 August 2025

Healthcare

Official sourceView documentsShare

Summary

Orphan Drug Act - Amends the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services to promulgate regulations to exempt from such Act drugs intended solely for drug treatment investigations. Defines "drug treatment investigation" as an investigation of a drug which involves human participants with a rare disease or condition. Establishes in the Department of Health and Human Services an interagency committee known as the Committee on Orphan Drug Development. Makes it the function of such committee to promote the development of drugs for rare diseases or conditions (orphan drugs). Requires the Director of the National Institutes of Health (NIH) to submit to the Committee an annual report on the rare disease and condition research activities of NIH. Requires the Secretary of the Treasury to submit to the Committee an annual report on the use of the tax credit for experimental expenses. Requires the Committee to report by June 1 of each year to the appropriate congressional committees on its activities and the results of its evaluations, including the report submitted by NIH and the Secretary of the Treasury. Amends the Internal Revenue Code to allow a tax credit for qualified experimental expenses incurred while researching orphan drugs.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 23 February 1982

    Introduced

    Read twice and referred to the Committee on Labor and Human Resources.

    Source: IntroReferral

  2. 23 February 1982

    Introduced

    Introduced in Senate

    Source: IntroReferral

  3. 26 February 1982

    Committee

    Committee on Labor and Human Resources requested executive comment from Health and Human Services Department; GAO; OMB.

    Source: Committee

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.